Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Evaluation of Hair Removal and Permanent Hair Reduction for Skin Types VI Using Intense Pulsed Light

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02452398
Recruitment Status : Terminated (Study withdrawn as technology already proven with data no longer needed.)
First Posted : May 22, 2015
Results First Posted : November 3, 2020
Last Update Posted : November 3, 2020
Sponsor:
Information provided by (Responsible Party):
Venus Concept

Brief Summary:
This is a Multi-center, blinded, baseline-controlled, prospective study to evaluate permanent hair reduction and removal for skin types V and VI using IPL.

Condition or disease Intervention/treatment Phase
Removal of Excess or Unwanted Body Hair Device: Treatment group Other: No intervention Not Applicable

Detailed Description:

One hundred and twenty (120) subjects who are Fitzpatrick Skin Type V-VI, and have a suitable treatment area for hair removal will be evaluated in this study.

Each subject will receive six treatments at four to six week intervals upon re-growth of hair and return for follow-up visits at one, three and six months after the last treatment.

Measurement Equipment Standard High Resolution Digital Camera

Labels for hair count Customized hair count sticker templates will be placed directly on the skin and the hairs in this window will be counted at specific visits during the study as detailed in section.

Study Procedures Each subject will participate in the study for a period of at least 11 months. The study is anticipated to be completed within twelve months.

Test spots Up to 3 test spots will be performed in the selected treatment area to determine the optimal parameters / setting.

Treatment

The treatment areas are divided into 3 groups. Each Subjects will be allocated to one of the following groups::

  • Two small anatomical areas (right and left axillae and double sided bikini line) or;
  • One double sided large area (right and left thighs) or;
  • One large area (whole back / abdomen)

Based on the mild nature of treatment, anesthesia is not required. Before starting treatment apply a layer of conductive gel to the treatment area.

After applying the conductive gel, locate the applicator in close contact, perpendicular to the skin with no pressure applied. Pressing the applicator will fire the IPL pulse. In order to ensure full coverage of the treatment area applicator placement should overlap approximately 1/3 of the previously treated skin.

Post-treatment Instructions Cold packs may be placed on the treated area for post treatment cooling. Subjects should be aware that post treatment erythema, edema and some discomfort of the treated areas are possible and should not be a cause for concern. They may also experience some purpura in the treated areas which would be expected to resolve within several days.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 79 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Clinical Evaluation of Hair Removal and Permanent Hair Reduction for Skin Types V-VI Using Intense Pulsed Light
Study Start Date : January 2015
Actual Primary Completion Date : March 27, 2017
Actual Study Completion Date : April 18, 2017

Arm Intervention/treatment
Experimental: Treatment Group
Hair removal treatment using Venus Versa IPL energy
Device: Treatment group
The intense pulsed light (IPL) applicator with a wavelength of 690 nm and spot size (treatment area) of 30 mm by 10 mm will be used to deliver the energy to the treatment area.

Other: No intervention
Subject will act as their own control where the baseline hair count will be used as a comparator to the hair count after treatment.

Placebo Comparator: No intervention
Subject hair count at baseline will act as the control to which the hair count at 6 months after the last treatment.
Other: No intervention
Subject will act as their own control where the baseline hair count will be used as a comparator to the hair count after treatment.




Primary Outcome Measures :
  1. Hair Count 6 Months Following Last Treatment [ Time Frame: 6 months after last treatment ]
    Hair count reduction in marked treatment area assessed from photographs taken 6 months following the last treatment as compared to photographs of the marked treatment area taken at baseline.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   21 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Able to read, understand and provide written Informed Consent;
  2. Subject has black or dark brown terminal hairs in the areas to be treated.
  3. Terminal hair density requirement of greater than 15 hairs within the hair count site (3x3 cm area) as determined by manual hair count performed by the study investigator.
  4. Healthy adult, male or female, 21 years of age or older with skin type V-VI;
  5. Having a suitable treatment area for hair removal;
  6. Able and willing to comply with the treatment/follow-up schedule and requirements;
  7. Women of child-bearing potential (women who have not had a hysterectomy, bilateral oophorectomy or are not postmenopausal) are required to be using a reliable method of birth control at least three months prior to enrollment and throughout the course of the study.

Exclusion Criteria:

  1. Subject has light ,gray terminal or fine hairs in all/some parts of the treated area;
  2. Pregnant, expectation of pregnancy, postpartum or nursing (<6 months);
  3. Hormonal disorders that may affect hair growth;
  4. Immunosuppressive diseases, including AIDS and HIV infection, or use of immunosuppressive medications;
  5. Livedo reticularis;
  6. Uncontrolled systemic diseases such as diabetes;
  7. Active infections in the treated area;
  8. Dysplastic nevi;
  9. Significant concurrent skin conditions or any inflammatory skin conditions;
  10. Active cold sores, open lacerations or abrasions;
  11. Chronic or cutaneous viral, fungal, or bacterial diseases;
  12. Current cancer;
  13. History of skin cancer or pre-cancerous lesions at the treatment areas;
  14. Use of Accutane™ (Isotretinoin) within the past six month;
  15. Keloid or Hypertrophic scar formation in the treatment area;
  16. Tattoos in the treatment area;
  17. Bleeding coagulopathies or use of anticoagulants;
  18. Auto-immune disorders;
  19. Erythema abigne, when identified treatments should be discontinued;
  20. Photosensitivity disorder that can be exacerbated by laser or intense light;
  21. Herpes simplex in the treatment area;
  22. Use of medications, herbal supplements, perfumes or cosmetics that may affect sensitivity to light;
  23. Poor wound healing;
  24. Sunburns;
  25. Unable or unlikely to refrain from artificial tanning, including the use of tanning booths, prior (at least a month) and during the course of the evaluation;
  26. Prior skin treatment with laser or other devices on the same treated areas within the last six months prior to study enrollment or during the course of the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02452398


Locations
Layout table for location information
United States, California
Dermatology and Laser Centre
Manhattan Beach, California, United States, 90266
Sponsors and Collaborators
Venus Concept
Investigators
Layout table for investigator information
Study Director: Tracey L Mancuso Venus Concept
  Study Documents (Full-Text)

Documents provided by Venus Concept:
Layout table for additonal information
Responsible Party: Venus Concept
ClinicalTrials.gov Identifier: NCT02452398    
Other Study ID Numbers: CS0115
First Posted: May 22, 2015    Key Record Dates
Results First Posted: November 3, 2020
Last Update Posted: November 3, 2020
Last Verified: October 2020
Keywords provided by Venus Concept:
Hair removal
depilation
epilation